NYSE •
Healthcare •
Biotechnology •
Quote as of 06/18/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization4.61 mln
Float16.18 mln
Earnings Date08/17/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
0.77
Transformational upside
Relative Strength
6
/ 100
Severely lagging
Debt / Equity
0.03
Debt-free
ROE
-255
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Azitra is a clinical-stage company based in Branford, Connecticut, focused on treating skin diseases through a novel approach: using a common skin bacterium, Staphylococcus epidermidis, that has been genetically modified to deliver therapeutic proteins directly to the skin. The company currently has three programs in development, targeting a rash caused by certain cancer treatments, Netherton syndrome, and ichthyosis vulgaris. Azitra also works with Bayer to identify and develop bacterial strains for use in topical products. Founded in 2014, the company represents an emerging approach to skin care that combines microbiology with precision medicine.
